Dallas, Texas 01/02/2014 (FINANCIALSTRENDS) – ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) is considered to be one of the top-line bio-pharma sub-junior companies, who will grow to a major player, one of its drugs is endorsed by FDA. It continues its cancer vaccine trials and has since reported that one patient has begun Phase I clinical trail for its vaccine which involves the dendritic cell.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) has been a prolific clinical-stage therapy development company which uses biotechnology to develop prospects which can render immunity against cancer causatives in the brain, ovary as well as tumours.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) has reported results for one of its major prospects- ICT-107, demonstrating that the progress of cancerous cell formation is stalled in the phaseII study. Called as Progression-free survival it was found that among patients administered ICT- 107 and placebo, the survival time average was found to be more than two months. However, the Progression-free survival was considered to be a secondary end-point. In the meanwhile, the Phase II trial was found to have failed to achieve the secondary end-point.
Earlier ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) ICT-107 studies by Cedars-Sinai for glioblastomamultiforme had shown that positive results – nearly half of the patients with this condition were found to survive beyond five years, after diagnosis. Additionally six of them were found to be free of progression after five years. More importantly, four patients were found to enjoy quality life with expectancy of 65.1 to 82.7 months after the diagnosis of the condition.
All treatment with ICT 107 involved patients who had just been diagnosed with Glioblastoma. IMUC had earlier concluded a service agreement with NeoStem, one of the subsidiaries of Progenitor Cell Therapy to provide cGMP for ICT-121 cell therapy, which involvd dendritic cell vaccine.
In the last week of December 2013, IMUC notched a good rally following the commencement of the first phase of study for ICT-121, with one patient receiving the treatment